The planned product, which will target drug-development companies, uses machine learning techniques to predict the outcomes and likelihood of success of clinical trials.
Molecular Health will make its analysis tools available to aid in the interpretation of raw data generated by customers of Agena's MassArray system.
The Workbench Manager helps labs manage their bioinformatics workflows while the Clinical Annotation software offers clinical variant interpretation services.
Molecular Health has renamed its portfolio ahead of planned product launches and an early-access program for its drug safety software starting in January.
The company will use the funds to continue building out its commercial platform and to drive product adoption.
Makers of NGS cancer profiling diagnostics lauded the preliminary proposal, but pointed out areas where the coverage criteria may miss patients who might benefit from testing.
The company's results add to a growing body of evidence, including from Foundation Medicine, that suggests such techniques have clinical utility for patients.
MolecularHealth announced that Fadi Braiteh has joined its advisory board. Braiteh is an oncologist with Comprehensive Cancer Centers of Nevada, specializing in gastro-intestinal, digestive system, and breast cancers.
Diagnostics firm Epic Sciences has appointed Greg Lucier as chairman of its board of directors.
An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.
In Science this week: reduction in bee phylogenetic diversity, and more.
The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.